The Cigna Group (CI) Q2 2026 earnings review
Specialty Boom Masks Pharmacy Transition Pains as Guidance Rises
Cigna delivered a solid Q2 2026, raising its full-year Adjusted EPS guidance to at least $30.45. Underneath the headline 6% earnings growth lies a profound internal shift: traditional Pharmacy Benefit Services (PBS) profits are contracting sharply (-27% YoY) as Cigna absorbs the costs of transitioning to its new 'Signature' rebate-free model and digests large client renewals. Fortunately, the Specialty and Care Services segment has officially eclipsed the PBM as the company's profit engine, surging 22% YoY. Meanwhile, Cigna Healthcare drove 17% profit growth on the back of strong U.S. Employer margins, successfully offsetting elevated medical cost trends.
🐂 Bull Case
With 22% YoY pre-tax income growth, Specialty & Care Services ($1.05B) has decisively overtaken the traditional PBM business ($609M) in profitability, validating management's aggressive pivot toward biosimilars and health system partnerships.
Despite a rising Medical Care Ratio (84.5%), Cigna Healthcare grew pre-tax income by 17%. Strong pricing discipline in the U.S. Employer business is driving highly efficient margin capture.
🐻 Bear Case
Evernorth grew top-line revenue by 6%, but total pre-tax profits fell 2%. The culprit is a 27% YoY collapse in PBS income, exposing the severe near-term financial friction of shifting to the new 'Signature' rebate-free model.
The MCR climbed 130 bps YoY to 84.5%. While partially distorted by prior-year individual exchange risk adjustments, the core structural headwind of high utilization persists across the industry.
⚖️ Verdict: 🟢
Bullish. Cigna is executing a difficult, highly disruptive PBM model transition while still raising enterprise earnings guidance. The explosive growth in Specialty offsets the PBM weakness, and SG&A discipline provides an excellent buffer against medical cost inflation.
Key Themes
The True Cost of the 'Signature' Transition
A specific data point contradicting the positive narrative is Evernorth's margin compression. Despite Pharmacy Benefit Services revenue growing 8% to $34.5B, its pre-tax income plummeted 27% YoY to $609M. Management has telegraphed that securing long-term renewals and implementing the new 'Signature' rebate-free PBM model would compress margins, but the magnitude is stark. Evernorth's overall pre-tax margin has now contracted from 2.9% in 25Q2 to 2.7% today.
Specialty & Care is the New Engine
Specialty and Care Services continues its relentless ascent, growing adjusted revenues by 4% to $27.0B and pre-tax income by 22% to $1.05B. The rapid adoption of generic alternatives and biosimilars (such as Humira and Stelara replacements) is delivering profound margin benefits. This segment now contributes nearly double the pre-tax income of the core PBM.
Cigna Healthcare's Pricing Power
The Cigna Healthcare segment demonstrated exceptional leverage. Adjusted revenues grew 9% to $11.7B due to disciplined premium rate increases designed to cover elevated medical costs. This pricing power flowed straight to the bottom line, driving a 17% increase in pre-tax income and expanding segment margin to 10.9% (up from 10.2% a year ago).
Elevated Medical Care Ratio (Macro)
The Medical Care Ratio (MCR) increased from 83.2% in 25Q2 to 84.5% in 26Q2. While the company attributed this primarily to lapping favorable prior-year risk adjustments in the Individual and Family Plans business, it underscores the persistent macro headwind of elevated healthcare utilization and structural cost inflation.
AI-Driven SG&A Efficiency
Cigna continues to extract massive operational leverage. The Adjusted SG&A ratio dropped from 4.9% in 25Q2 to 4.6% in 26Q2. As noted by CEO Brian Evanko in prior quarters, this is structurally supported by the integration of agentic AI for prescription processing and digital tools that have actively reduced inbound call volumes by 20-25%.
Exiting the ACA Exchanges
The previously announced strategic exit from the Individual and Family Plans medical business (effective Jan 1, 2027) casts a shadow over Cigna Healthcare's near-term metrics. While this will eliminate a source of MCR volatility and low-margin noise, it requires careful management of customer transitions over the next two quarters.
Other KPIs
Up 6% YoY from $1.9 billion in 25Q2. Translates to $7.78 per share. This indicates stable, durable earnings generation despite significant disruptions in the PBM business model.
Increased 2% from December 31, 2025. Growth was driven primarily by gains in the Middle and Select markets, successfully offsetting intentional pullbacks and lower membership in National Accounts.
Through July 29, 2026, Cigna repurchased 0.9 million shares. This is a significantly slower pace compared to 2025 (where they repurchased 11.9 million shares for $3.6B), though the 2026 guidance suggests repurchases will likely be back-half weighted alongside cash flow generation.
Guidance
Accelerating. Raised from the Q1 projection of 'at least $30.35'. Implies approximately 2% growth over FY25's $29.84, which remains impressive given the planned margin compression in the Pharmacy segment.
Stable. Maintained from prior guidance. However, because H1 2026 only generated $3,129 million, hitting this target requires a massive acceleration in the second half of the year ($3,771 million), heavily dependent on Specialty & Care momentum.
Accelerating. Raised by $25 million from the prior 'at least $4,525M' guide, reflecting confidence in U.S. Employer pricing power and ongoing margin expansion despite MCR volatility.
Stable. Maintained from prior guidance. The Q2 actual of 84.5% sits near the top end of this range, suggesting Cigna expects utilization to normalize or pricing adjustments to catch up in the back half of the year.
Key Questions
Evernorth's Back-Half Acceleration
Full-year guidance for Evernorth requires roughly $3.77B in pre-tax income in H2 vs $3.13B generated in H1. Given the 27% YoY decline in PBS this quarter, what specific catalysts give you confidence in this steep back-half ramp?
PBM Margin Floor
Pharmacy Benefit Services profits fell 27% year-over-year. As we approach the broader rollout of the 'Signature' model in 2027 and 2028, have we reached the floor for PBS margins, or should we expect further compression as transition costs scale?
Biosimilar Pipeline Impact
Specialty & Care Services is exhibiting incredible 22% profit growth, heavily aided by biosimilar adoption for Humira and Stelara. What does the pipeline for the next 12-18 months look like, and can this rate of growth be sustained as those initial conversion waves annualize?
MCR Clean-Up Post-Exchange Exit
With the planned exit from the Individual and Family Plans market in 2027, how much of the current 84.5% MCR pressure do you estimate will organically roll off the books next year?